Thomas E. Lew

1.4k total citations · 1 hit paper
33 papers, 880 citations indexed

About

Thomas E. Lew is a scholar working on Genetics, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Thomas E. Lew has authored 33 papers receiving a total of 880 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Genetics, 13 papers in Pathology and Forensic Medicine and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Thomas E. Lew's work include Chronic Lymphocytic Leukemia Research (20 papers), Lymphoma Diagnosis and Treatment (12 papers) and Advanced Breast Cancer Therapies (6 papers). Thomas E. Lew is often cited by papers focused on Chronic Lymphocytic Leukemia Research (20 papers), Lymphoma Diagnosis and Treatment (12 papers) and Advanced Breast Cancer Therapies (6 papers). Thomas E. Lew collaborates with scholars based in Australia, United States and Taiwan. Thomas E. Lew's co-authors include John F. Seymour, Constantine S. Tam, Andrew W. Roberts, Mary Ann Anderson, David Westerman, Piers Blombery, David C.S. Huang, Ella R. Thompson, Tamia Nguyen and Sasanka M. Handunnetti and has published in prestigious journals such as Journal of Clinical Oncology, Blood and British Journal of Haematology.

In The Last Decade

Thomas E. Lew

31 papers receiving 871 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

2018 276 citations Piers Blombery, Mary Ann Anderson et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas E. Lew Australia	16	573	428	219	211	198	33	880
Fong Clow United States	14	814 1.4×	801 1.9×	153 0.7×	340 1.6×	292 1.5×	30	1.2k
Zeena Salman United States	10	304 0.5×	268 0.6×	139 0.6×	163 0.8×	102 0.5×	27	576
Lucy S. Hodge United States	15	231 0.4×	271 0.6×	161 0.7×	71 0.3×	298 1.5×	30	812
Hassan El‐Solh Saudi Arabia	15	97 0.2×	164 0.4×	261 1.2×	169 0.8×	86 0.4×	40	693
Joo-Seop Chung South Korea	14	155 0.3×	310 0.7×	67 0.3×	213 1.0×	200 1.0×	46	690
Eleanor V. Willett United Kingdom	14	153 0.3×	408 1.0×	281 1.3×	184 0.9×	103 0.5×	22	1.0k
Diane Warren United States	12	528 0.9×	432 1.0×	348 1.6×	525 2.5×	214 1.1×	40	1.0k
Emel Aygören‐Pürsün Germany	26	1.9k 3.4×	680 1.6×	287 1.3×	699 3.3×	395 2.0×	93	2.2k
Jacek Treliński Poland	12	206 0.4×	110 0.3×	115 0.5×	394 1.9×	78 0.4×	50	639
Pascal Lenain France	14	336 0.6×	338 0.8×	683 3.1×	859 4.1×	99 0.5×	40	1.3k

Countries citing papers authored by Thomas E. Lew

Since Specialization

Citations

This map shows the geographic impact of Thomas E. Lew's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Lew with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Lew more than expected).

Fields of papers citing papers by Thomas E. Lew

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas E. Lew. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Lew. The network helps show where Thomas E. Lew may publish in the future.

Co-authorship network of co-authors of Thomas E. Lew

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas E. Lew. A scholar is included among the top collaborators of Thomas E. Lew based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas E. Lew. Thomas E. Lew is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cliff, Edward R. Scheffer, Thomas E. Lew, Florian Simon, et al.. (2025). Optimizing Control Arms in Chronic Lymphocytic Leukemia Clinical Trials: The BRUIN-CLL-321 Trial. Journal of Clinical Oncology. 44(3). 254–256.

Lew, Thomas E., Victor S. Lin, Sasanka M. Handunnetti, et al.. (2024). Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon. Blood Advances. 8(6). 1439–1443. 6 indexed citations

Lew, Thomas E., Edward R. Scheffer Cliff, Michael Dickinson, et al.. (2023). Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53 -mutated disease. Leukemia & lymphoma. 64(11). 1792–1800. 5 indexed citations

Lew, Thomas E., Adrian Minson, Michael Dickinson, et al.. (2023). Treatment approaches for patients with TP53-mutated mantle cell lymphoma. The Lancet Haematology. 10(2). e142–e154. 17 indexed citations

Lew, Thomas E. & John F. Seymour. (2022). Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination. Journal of Hematology & Oncology. 15(1). 75–75. 31 indexed citations

Blombery, Piers, Ella R. Thompson, Thomas E. Lew, et al.. (2022). Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance. Blood Advances. 6(20). 5589–5592. 62 indexed citations

Amatya, Bhasker, Fary Khan, Thomas E. Lew, & Michael Dickinson. (2021). Rehabilitation in patients with lymphoma: An overview of Systematic Reviews. Journal of Rehabilitation Medicine. 53(3). jrm00163–jrm00163. 18 indexed citations

Lew, Thomas E., Mary Ann Anderson, Victor S. Lin, et al.. (2020). Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months. Blood Advances. 4(1). 165–173. 31 indexed citations

Lew, Thomas E., Mary Ann Anderson, & John F. Seymour. (2020). Promises and pitfalls of targeted agents in chronic lymphocytic leukemia. Cancer Drug Resistance. 3(3). 415–444. 8 indexed citations

10.

Lin, Victor S., Thomas E. Lew, Sasanka M. Handunnetti, et al.. (2020). BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax. Blood. 135(25). 2266–2270. 61 indexed citations

11.

Potter, Elizabeth, et al.. (2019). Evaluation of pharmacist‐led physician‐supported inpatient deprescribing model in older patients admitted to an acute general medical unit. Australasian Journal on Ageing. 38(3). 206–210. 14 indexed citations

12.

Chang, Chee‐Jen, et al.. (2019). The Cost of Hypoglycemia Associated With Type 2 Diabetes Mellitus in Taiwan. Value in Health Regional Issues. 18. 84–90. 3 indexed citations

13.

Blombery, Piers, Mary Ann Anderson, Jianan Gong, et al.. (2018). Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discovery. 9(3). 342–353. 276 indexed citations breakdown →

14.

Lew, Thomas E., Mary Ann Anderson, Constantine S. Tam, et al.. (2018). Long Term Outcomes of Venetoclax Therapy for Complex Karyotype Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 132(Supplement 1). 4431–4431. 1 indexed citations

15.

Polkinghorne, Kevan R., et al.. (2017). Early serum creatinine accurately predicts acute kidney injury post cardiac surgery. BMC Nephrology. 18(1). 93–93. 16 indexed citations

16.

Lew, Thomas E., et al.. (2016). Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study. Diabetes Metabolic Syndrome and Obesity. Volume 9. 243–249. 18 indexed citations

17.

Lin, Huan, et al.. (2016). The Cost-Effectiveness of Dulaglutide Versus Liraglutide in Patients with Type 2 Diabetes Mellitus in Taiwan. Value in Health. 19(7). A898–A898. 1 indexed citations

18.

Lew, Thomas E., Mary Ann Anderson, Constantine S. Tam, et al.. (2016). Clinicopathological Features and Outcomes of Progression for Chronic Lymphocytic Leukaemia (CLL) Treated with the BCL2 Inhibitor Venetoclax. Blood. 128(22). 3223–3223. 1 indexed citations

19.

Lew, Thomas E., Chan Y. Cheah, Dennis Carney, et al.. (2015). Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy. Leukemia & lymphoma. 57(5). 1044–1053. 2 indexed citations

20.

Cheah, Chan Y., Thomas E. Lew, John F. Seymour, & Kate Burbury. (2013). Rasburicase Causing Severe Oxidative Hemolysis and Methemoglobinemia in a Patient with Previously Unrecognized Glucose-6-Phosphate Dehydrogenase Deficiency. Acta Haematologica. 130(4). 254–259. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact